View Post

CDK4/6 Inhibitors Reach New Benchmarks in Overall Survival in HR+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Anita T. Shaffer From: onclive.com The release of new evidence that CDK4/6 inhibition results in survival gains for patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer marks a new milestone for the therapeutic approach and may help set the stage for expanding use of these agents into earlier clinical settings. The big news for this class of therapy …

View Post

What You Need to Know About the FDA’s Approval of Nerlynx-Xeloda Combo for HER2-Positive Breast Cancer

In In The News by Barbara Jacoby

By: Conor Killmurray From: curetoday.com The Food and Drug Administration (FDA) recently approved the supplemental new drug application for the combination of Nerlynx (neratinib) and Xeloda (capecitabine) for the treatment of adults with advanced or metastatic HER2-positive breast cancer who previously received two or more anti-HER2-based therapies in the metastatic setting. The agency based its approval on data from the …

View Post

Patient-Driven Solutions May Lead to Greater Metastatic Breast Cancer Clinical Trial Participation

In Clinical Studies News by Barbara Jacoby

By: John Schieszer From: oncologynurseadvisor.com Findings from a patient-led study suggest that adopting a collaborative, systematic, solutions-based approach may enable more patients with metastatic breast cancer (MBC) to participate in clinical trials. The rate of participation in clinical trials for breast cancer is dismally low, which is slowing drug development and adding to overall costs. However, more patients living with …

View Post

Connecting To Clinical Trials

In In The News by Barbara Jacoby

By: Martha Carlson From: curetoday.com Martha lives in Illinois and was diagnosed with metastatic breast cancer in January 2015. She has a husband and three children, ranging in age from 12 to 18, a dog and a lizard. My family will tell you that after years of refusing a cell phone, I was persuaded to buy one – and carry …

View Post

Early data signal immunopriming effect of bevacizumab in advanced breast cancer

In Clinical Studies News by Barbara Jacoby

By: Shreeya Nanda From: medwirenews.com Combined treatment with durvalumab plus bevacizumab could benefit women with HER2-negative advanced breast cancer who have progressed on bevacizumab maintenance, shows a phase 1b trial. In addition to promising efficacy and tolerability data, the researchers also report on correlative studies, which they say “agree with the preclinical rationale supporting an immunopriming effect exerted by antiangiogenic …

View Post

Cancer patients find clinical trials, hope and help

In Clinical Studies News by Barbara Jacoby

By: Diane Mapes From: fredhutch.org #NWMetsConf connects metastatic breast cancer patients with trials, treatments, tools and each other Clinical trials — the treatments of tomorrow, today — took top billing at the fourth annual Northwest Metastatic Breast Cancer Conference held Saturday at the Amazon Meeting Center in Seattle. Scientists from Fred Hutchinson Cancer Research Center shared new treatments; National Cancer …